key: cord-1008937-7wgl9fom
authors: Gupta, Yashdeep; Goyal, Alpesh; Kubihal, Suraj; Golla, Kiran Kumar; Tandon, Nikhil
title: A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India
date: 2021-02-03
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.01.015
sha: 06ba9edf2cb09d6e3ed680dffe60abf794ea6acf
doc_id: 1008937
cord_uid: 7wgl9fom

BACKGROUND AND AIMS: Diabetes and coronavirus disease 2019 (COVID-19) share a bidirectional relationship. Hyperglycemia occurring in the setting of either previously diagnosed or undiagnosed diabetes is known to be associated with poor outcomes. Here, we aim to provide a simple and practical guidance on the diagnosis and management of hyperglycemia in admitted patients with COVID-19. METHODS: The guidance is formulated based on experience of authors and relevant literature on the subject searched using Pubmed. RESULTS: Every patient admitted to a COVID care facility should be investigated for hyperglycemia using a combination of tests including capillary blood glucose, fasting plasma glucose and HbA1c. Oral glucose lowering drugs can be considered in patients with mild COVID illness who have mild hyperglycemia (pre-meal blood glucose of ≥180 mg/dl and post-meal blood glucose of ≥250 mg/dl) and no contraindication to the use of these agents. All patients with moderate-severe disease and/or hyperglycemia of greater severity should be initiated on insulin therapy. Hyperglycemia should be aggressively screened for and managed in patients receiving systemic glucocorticoids. CONCLUSION: This document provides a broad overview on the diagnosis and management of hyperglycemia at COVID care facilities and should be useful to a wide range of healthcare personnel involved in care of patients with COVID-19.

Since the report of the first case from Wuhan, China Diabetes has been reported to be a major comorbidity among patients with COVID-19. The pooled prevalence of diabetes among patients with COVID-19 was reported to 11.5% (95 % CI, 9.5 to 13.4) in a recent meta-analysis [3] . The meta-analysis also found that patients with diabetes were more likely to encounter severe COVID-19 [HR 2.11 (95% CI, 1.40, 3.19) ].

Another recent meta-analysis has reported that diabetes is not only associated with increased disease severity [OR 2.35 (95% CI 1.80, 3.06)], but also increased mortality [OR 2.50 (95% CI 1.74, 3.59)] [4] . Besides, fasting blood glucose (FBG) has been reported to be an independent predictor of mortality among patients with COVID- 19 [5] . Hospitalised patients with COVID-19 who have optimal blood glucose control (glycemic variability within 70-180 mg/dl) are likely to have 10-fold lower mortality, compared to those with poor blood glucose control (upper limit of glycemic variability >180 mg/dl) [6] . Adults diagnosed with diabetes during the COVID-19 outbreak have been reported to present with more severe glycemia compared to those diagnosed before the outbreak [7] . Given that India has a huge burden of diabetes, and nearly half of the patients with diabetes remain undiagnosed, the challenges for our healthcare system are enormous [8, 9] . The need of the hour is to not only improve the care for patients with pre-existing diabetes, but also to actively screen for and aggressively manage patients with undiagnosed diabetes and stress hyperglycemia [10] .

Previous reviews published in this journal and elsewhere have highlighted the following issues relevant to COVID-19: a) relationship between COVID-19 and diabetes/other comorbidities [11] [12] [13] [14] , b) appropriate diagnosis and management of diabetes and other endocrine disorders during the pandemic [15] [16] [17] [18] [19] [20] [21] , and c) the evolving role of telemedicine consultations in the era of COVID-19 and its pitfalls [22, 23] . Given the huge burden of J o u r n a l P r e -p r o o f COVID-19 in our country, expertise for close supervision of diabetes management may not always be available and treatment decisions may need to be taken by non-experts or healthcare personnel from a non-clinical specialty deployed in COVID facilities. This review aims to provide a simple and practical guidance on the diagnosis and management of hyperglycemia, including steroid induced hyperglycemia in COVID-19, which could be helpful to a broad range of healthcare personnel caring for such patients.

Every patient admitted to a COVID care facility should be investigated for hyperglycemia on the day of admission itself (figure 1). We suggest performing a random glucose value with a reliable blood glucose meter (step 1) at the time of receiving or admitting the patient in the facility. If the capillary blood glucose value is ≥ 180 mg/dl, one should be suspicious of underlying diabetes/stress hyperglycemia. In step 2, we suggest monitoring pre-meal and 2hour post meal capillary glucose around the first major meal consumed after the admission. If the pre-meal value is ≥ 140 mg/dl and/or post-meal value is ≥ 180 mg/dl, we suggest initiation of regular blood glucose monitoring (4-6 times a day). In step 3, we suggest sending a blood sample for fasting plasma glucose (FPG) estimation to a laboratory on the day following admission. If the facilities are available, glycated hemoglobin (HbA1c) measurement should also be considered. A value of FPG ≥ 110 mg/dl has been found to be associated with increased mortality, and warrants further monitoring of capillary glucose over the next two days [5] (step 2). Patients without a previous diagnosis of diabetes and a current HbA1c of ≥6.5% should be classified as having undiagnosed diabetes, while those without known diabetes, but with documented in-hospital hyperglycemia and a HbA1c value of <6.5% should be classified as having stress hyperglycemia [24] . [25] . The goal of a stringent screening policy should therefore be to identify individuals with undiagnosed diabetes and stress hyperglycemia (or new-onset hyperglycemia) who are often missed and J o u r n a l P r e -p r o o f eventually fare poorly in terms of disease outcomes and mortality rates, compared to their counterparts with diagnosed diabetes [26] [27] [28] .

The previous section detailed the glycemic assessment of an individual at the time of admission (and on a subsequent day) in order to uncover stress hyperglycemia or undiagnosed diabetes. However, we know that a patient with normal initial glycemic profile may develop stress hyperglycemia during the course of illness, especially if the individual moves up the COVID severity ladder. Besides, institution of glucocorticoids for treatment of primary disease may also contribute to hyperglycemia in such an individual [29, 30] . Thus, glycemic assessment should be an ongoing dynamic process and not a one-time event (figure 2).

According to the available guidance from multiple professional organizations, in general, insulin therapy should be preferred in hospitalized patients. However, considering the situation in our country, expert care may not always be available, and switching all patients on oral glucose-lowering agents to insulin may not be feasible. Therefore, in the absence of compelling indications for the use of insulin, we suggest that oral glucose-lowering agents can be continued. An ideal candidate would be one with mild COVID illness who does not have any contraindication for the continuation of oral drugs (such as renal or liver dysfunction), and has mild hyperglycemia (pre-meal blood glucose < 180 mg/dl and postmeal blood glucose < 250 mg/dl) (figure 3). The initiation of oral antihyperglycemic agents can be considered in patients with newly detected hyperglycemia (e.g., undiagnosed diabetes or stress hyperglycemia), who meet the above thresholds.

In line with other guidelines, we suggest stopping SGLT-2 inhibitors due to the risk of dehydration and euglycemic diabetic ketoacidosis [16] . We also suggest stopping pioglitazone due to its fluid retaining properties, which may be detrimental, especially in individuals on insulin, and those with myocardial dysfunction. Metformin carries a risk of lactic acidosis in the presence of renal insufficiency, hypoxia, and hemodynamic instability, and should be discontinued if these conditions are present. Sulfonylurea (SU) cause blood glucose-independent insulin release, and can therefore result in hypoglycemia in patients with J o u r n a l P r e -p r o o f poor oral intake or erratic diet pattern. Considering their relative safety, dipeptidyl peptidasedisease [15, 16] . In low resource settings like ours, vildagliptin and teneligliptin may be preferred over sitagliptin and linagliptin due to their low cost.

We suggest initiation of insulin therapy in individuals with moderate to severe COVID due to its relative safety and efficacy. We also suggest insulin therapy if there is little possibility of achieving euglycemia in the short-term with initiation or up-titration of DPP-4 inhibitors, metformin, and sulphonylureas (e.g., pre-meal blood glucose of ≥ 180 mg/dl and post-meal 

Patient who were already on basal-bolus regimen prior to admission should be continued on the same and insulin doses should be adjusted according to blood glucose monitoring. 

Following the emergence of positive results from the RECOVERY trial [31] , the use of glucocorticoids among patients with COVID-19, especially those with moderate-severe disease, has increased significantly. The use of high dose glucocorticoids is associated with an increased risk of hyperglycemia, which is often challenging to manage. Even patients who have previously well-controlled blood glucose levels may require large doses of insulin (e.g., Patients with diabetes who maintain their blood glucose levels with oral glucose-lowering agents during admission can be discharged on the same medications with advice for periodic follow-up. Patients who were on basal bolus insulin regimen and required relatively high doses (e.g., >1 unit/kg/day) should preferably be discharge on given insulin regimen itself, albeit with reduction in total insulin dose. On the other hand, individuals on insulin dose between 0.5 and 1 units/kg/day can be discharged on twice daily pre-mix insulin and oral glucose-lowering agents. Finally, patients who required only low doses of insulin (e.g., < 0.5 units/kg/day) and no other medications to control hyperglycemia may be discharged on oral glucose-lowering agents like DPP-4 inhibitor, metformin, SUs, after careful consideration of drug safety. At discharge, the patient should be provided appropriate diabetes education, especially on diet, and lifestyle management, self-monitoring of blood glucose and hypoglycemia care. Patients discharged on insulin should be educated regarding injection technique, storage, blood glucose log maintenance, and dose adjustment based on blood glucose readings. The discharge summary should provide a detailed account of comorbid situations, advised medications, any specific instructions, and time for the next consultation which could be either in-person or telephonic.

This guidance document provides a broad overview on the diagnosis and management of hyperglycemia at COVID care facilities and should be useful to a wide range of healthcare personnel involved in care of patients with COVID-19.

YG, AG and NT conceived the idea of this paper. YG and AG wrote the first draft of the manuscript which was read and edited by SK, KG and NT. The figures were prepared by YG using paid prescription from Biorender.com. All authors approved the final version of the manuscript. 

Government of India: COVID-19 Updates

Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a metaanalysis

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2

Glycemic parameters in new-onset diabetes during COVID-19 pandemic are more severe than new-onset diabetes before the pandemic: NOD COVID India study

Diabetes Federation. IDF Diabetes Atlas-9TH edition

Strict glycemic control is needed in times of COVID19 epidemic in India: A Call for action for all physicians

Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Obesity in patients with COVID-19: a systematic review and meta-analysis

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

COVID-19 and Diabetes: A Collision and Collusion of Two Diseases

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature

Practical recommendations for the management of diabetes in patients with COVID-19

Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India

COVID-19 and endocrine diseases. A statement from the

Managing common endocrine disorders amid COVID-19 pandemic

Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians

Pitfalls in telemedicine consultations in the era of COVID 19 and how to avoid them

Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society clinical practice guideline

High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in

and their association with outcomes

Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration

Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 Study

At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19

Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes

COVID-19 and steroid therapy: Impact on diabetes

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report